

Botox® (onabotulinumtoxinA) – Expanded indication

- On October 18, 2019, the <u>FDA approved</u> Allergan's <u>Botox (onabotulinumtoxinA)</u>, for the treatment of lower limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy.
 - Previously, Botox was approved for adult patients for lower limb spasticity.
- Botox is also approved for the treatment of overactive bladder, urinary incontinence due to detrusor
 overactivity, prophylaxis of headaches in adult patients with chronic migraine, treatment of upper
 limb spasticity in adult and pediatric patients 2 to 17 years of age, treatment of cervical dystonia in
 adult patients, treatment of severe axillary hyperhidrosis, treatment of blepharospasm, and treatment
 of strabismus.
- The expanded indication was approved based on a double-blind, placebo-controlled study of 381
 pediatric patients with lower limb spasticity. The co-primary endpoints were the average of the
 change from baseline in modified Ashworth Scale (MAS) ankle score, and the average of the Clinical
 Global Impression of Overall Change by Physician (CGI) at week 4 and week 6.
 - The week 4 and 6 average MAS score was -1.01 and -1.06 for the Botox 4 units/kg dose and 8 units/kg dose, respectively vs. -0.80 for the placebo dose (p < 0.05 for the 8 units/kg dose vs. placebo).
 - The week 4 and 6 average CGI score was 1.49 and 1.65 for the Botox 4 units/kg dose and 8 units/kg dose, respectively vs. 1.36 for the placebo dose (p < 0.05 for the 8 units/kg dose vs. placebo).
- Botox carries a boxed warning for distant spread of toxin effect.
- The most common adverse effect (≥ 5% and > placebo) with Botox use in pediatric spasticity was upper respiratory tract infection.
- The recommended dose for treating pediatric lower limb spasticity is 4 units/kg to 8 units/kg divided among the affected muscles. The total dose of Botox administered per treatment session in the lower limb should not exceed 8 units/kg or 300 units, whichever is lower.
 - When treating both lower limbs or the upper and lower limbs in combination, the total dose should not exceed the lower of 10 units/kg body weight or 340 units, in a 3-month interval.
- Consult the Botox drug label for dosing recommendations for all additional indications.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.